

Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets

London, 12 February 2024 – [Hikma Pharmaceuticals PLC](#) (Hikma), the multinational pharmaceutical company, has announced that it has recently signed an exclusive licencing agreement with [AFT Pharmaceuticals](#) (AFT) for the registration and commercialization of Combogesic® IV, an intravenous, opioid-free pain relief medicine for the short term symptomatic treatment of acute pain in adults and the reduction of fever, in Saudi Arabia, Jordan, and Iraq. It is a patented intravenous formulation of Paracetamol 1000mg + Ibuprofen 300mg solution for infusion.

The new agreement provides Hikma with exclusive rights for the commercialisation of Combogesic® IV in the three countries. A similar agreement has been previously signed with AFT Pharmaceuticals in the US market and the launch of Combogesic® IV in the US market has been announced earlier this month.

Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: "Our agreement with AFT Pharmaceuticals for Combogesic® IV – an important alternative for the treatment of acute pain and fever – is an important milestone in delivering on our purpose of putting better health, within reach, every day. As a leading healthcare company in MENA, we continue to expand our pipeline in growing therapeutic areas and are committed to partnerships with global players to expand our portfolio of high-quality medicines to patients in the region."

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Mona Abdallah
Senior Director, MENA Communications

+ 962 6 5802900
MBAbdallah@Hikma.com

About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major

hikma.

pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Their product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.